Industry Experts

Prof. Tobias Pöhlmann is a trained biologist and received his PhD in cancer biology from the Friedrich Schiller University Jena in 2005. He built a strong scientific network during his time as a scientist at the Ontario Veterinary College in Guelph, Ontario, Canada and at the Marine Biological Laboratory in Woods Hole, Massachusetts, USA. In the European Network of Excellence on Embryo Implantation Control he was responsible for RNAi experiments, which provided the perfect environment to start the work on RNAi-based therapeutic strategies. In 2012, Dr. Pöhlmann co-founded BianoScience to develop a peptide-siRNA prodrug for the treatment of breast cancer, and in 2017 BianoGMP, an oligonucleotide CDMO company. In January 2025, Prof. Pöhlmann started XNAPharma, a pharma company focused on the preclinical development and formulation as well as clinical development of oligonucleotide based drugs to treat ovarian cancer as well as for rare and ultra-rare (N=1) diseases